President Trump may have used the bully pulpit to force Pfizer (PFE) to roll back a bunch of price hikes last July, but the drug maker now expects “business as normal” once January rolls around.

In an earnings conference call, Pfizer Chief Executive Officer Ian Read was asked about pricing going forward because the Trump administration has floated a few ideas to combat high costs, but taken little action. And so, Wall Street has been expecting drug companies — nearly all of which also hit the pause button on price hikes this past summer — will likely revert to their normal practice of raising prices each Jan. 1.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy